細菌性膣症(Bacterial Vaginosis):治療薬パイプラインレビュー

Global Markets Directが発行した調査報告書(GMDHC10625IDB)
◆英語タイトル:Bacterial Vaginosis - Pipeline Review, H2 2018
◆商品コード:GMDHC10625IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年7月17日
◆ページ数:62
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Bacterial Vaginosis – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis – Pipeline Review, H2 2018, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis – Overview
Bacterial Vaginosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Bacterial Vaginosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bacterial Vaginosis – Companies Involved in Therapeutics Development
Evofem Biosciences Inc
Melinta Therapeutics Inc
Osel Inc
Pharmiva AB
Profarma
Starpharma Holdings Ltd
Bacterial Vaginosis – Drug Profiles
Amphora – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clindamycin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LACTIN-V – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metronidazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Bacterial Vaginosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radezolid – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Bacterial Vaginosis and Candidiasis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
subtilosin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNP-2198 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-463 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Vaginosis – Dormant Projects
Bacterial Vaginosis – Discontinued Products
Bacterial Vaginosis – Product Development Milestones
Featured News & Press Releases
Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV
Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes
Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US
Oct 25, 2017: VivaGel BV granted marketing approval in Australia
Aug 07, 2017: Successful VivaGel Phase 3 results and NDA planned for rBV
Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy
Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation
Jun 29, 2017: AMPHORA (L-lactic Acid, citric acid, and potassium bitartrate) Receives “Qualified Infectious Disease Product” (QIDP) Designation from the FDA
Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed
Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA
Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program
Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH
Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health
May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Bacterial Vaginosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, H2 2018
Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, H2 2018
Bacterial Vaginosis - Pipeline by Osel Inc, H2 2018
Bacterial Vaginosis - Pipeline by Pharmiva AB, H2 2018
Bacterial Vaginosis - Pipeline by Profarma, H2 2018
Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H2 2018
Bacterial Vaginosis - Dormant Projects, H2 2018
Bacterial Vaginosis - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Bacterial Vaginosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 細菌性膣症(Bacterial Vaginosis):治療薬パイプラインレビュー(Bacterial Vaginosis - Pipeline Review, H2 2018)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆